PRINT OUT

Product Pipeline

Nov 06. 2017

<Domestic>

Stage Code No.
(Generic name)
Therapeutic field Indications Origin Development
NDA filing GA101
(obinutuzumab)
hematologic malignancies follicular lymphoma Licensed‐in from
Chugai Pharmaceutical Co., Ltd.
Co‐developed with
Chugai Pharmaceutical Co., Ltd.
Phase III NS-304
(selexipag)
intractable disease・
orphan disease
chronic thromboembolic pulmonary
hypertension
Nippon shinyaku Co‐developed with
Actelion Pharmaceuticals Japan Ltd.
Phase II NS-304
(selexipag)
cardiovascular arteriosclerosis obliterans Nippon shinyaku Nippon shinyaku
Phase II NS-580 gynecology endometriosis Nippon shinyaku Nippon shinyaku
Phase I/II NS-065/
NCNP-01
intractable disease・
orphan disease
duchenne muscular dystrophy Co-development:
National Center of Neurology and Psychiatry
Nippon shinyaku
Phase I NS-32 gynecology iron deficiencyanemia Licensed‐in from
Pharmacosmos A/S
Nippon shinyaku
Preparation for development NS-917 hematologic malignancies relapsed/refractory acute myeloid leukemia Licensed‐in from
Delta-Fly Pharma, Inc.
Nippon shinyaku
Preparation for development NS-73 hematologic malignancies veno-occlusive disease Licensed‐in from
Jazz Pharmaceuticals plc
Nippon shinyaku
Preparation for development NS-87 hematologic malignancies secondary acute myeloid leukemia Licensed‐in from
Jazz Pharmaceuticals plc
Nippon shinyaku

<Overseas>

Stage Code No.
(Generic name)
Therapeutic field Indications Origin Development
China
NDA filing
NM441
(prulifloxacin)
anti-infection bacterial infections Nippon shinyaku Licensed‐out to
Lee's Pharmaceutical Holdings Limited
Phase II NS-065/
NCNP-01
intractable disease・
orphan disease
duchenne muscular dystrophy Co-development:
National Center of Neurology and Psychiatry
Nippon shinyaku
Phase I/II NS-018 hematologic malignancies myelofibrosis Nippon shinyaku Nippon shinyaku
page-top